You have read all your free articles, to continue reading subscribe to read the rest of this content.
Oncopeptides has announced that the full top-line results from the phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma (RRMM), have been presented at the ongoing 25th European Hematology Association meeting, Already a subscriber Login You have read all your free…
Danish biotech company Orphazyme raised a €20 million ($24 million US) B round to pay for its work on rare lysosomal storage disorders as it moves toward Phase II trials. Investors included Novo Nordisk's venture arm. Orphazyme's lead candidate, Orph002, is a treatment for Niemann-Pick diseasAlready a subscriber Login You…
AstraZeneca has announced two new randomised, placebo-controlled Phase IIIb outcome trials with Forxiga (dapagliflozin), an SGLT-2 inhibitor currently indicated for the treatment of type-2 diabetes. These two large outcome trials will help to define the potential role of dapagliflozin in the manaAlready a subscriber Login You have read all your…
Nordic Nanovector's Betalutin continues to show promising efficacy and increasing Duration of Response. Nordic Nanovector, a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology, announces updated results of its ongoing Phase 1/2 study with BeAlready a subscriber Login You have read all your free…
